Optimization of factor VIII replacement therapy: can structural studies help in evading antibody inhibitors?
Spiegel
P Clint
PC
Graduate Program in Biomolecular Structure and Design, University of Washington, Division of Basic Sciences, Fred Hutchinson Cancer Research Center, Seattle 98109, USA.
Stoddard
Barry L
BL
D000818:Animals; D019774:Blood Coagulation Factor Inhibitors / Q000378:metabolism; D018360:Crystallography, X-Ray; D004285:Dogs; D000939:Epitopes; D005169:Factor VIII / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D008297:Male; D051379:Mice; D009154:Mutation; D011994:Recombinant Proteins / Q000627:therapeutic use; D017385:Sequence Homology; D013329:Structure-Activity Relationship; D013552:Swine
D019774:Blood Coagulation Factor Inhibitors; D000939:Epitopes; D011994:Recombinant Proteins; D005169:Factor VIII